ADXN

NASDAQ 已收盘

Addex Therapeutics

3.47 USD
▲+0.07+2.06%
盘后 3.22 -7.20%
2026-11-20
市值
$6.38M
市盈率
—
EPS
-8.31
股息率
—
52 周区间
2.56 – 10.43
成交量
18.14K
Beta
2.07
目标价
—
52W 低 2.5652W 高 10.43
价格走势

公司简介

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, ad...